Lentiviral Mediated Delivery of shRNAs to hESCs and NPCs Using Low-cost Cationic Polymer Polyethylenimine (PEI)
May 24th, 2022
2.7K views
Using the low-cost cationic polymer polyethylenimine (PEI), we produced lentiviral particles for stable expression of shRNAs in H9 human embryonic stem cells (hESCs) and transiently transduced H9-derived neural progenitor cells (NPCs) at high efficiency.
Overview
This study explores the use of the cationic polymer polyethyleneimine (PEI) for producing lentiviral particles that facilitate stable expression of short hairpin RNAs (shRNAs) in H9 human embryonic stem cells (hESCs). The approach demonstrates high efficiency in transiently transducing H9-derived neural progenitor cells (NPCs).
Key Study Components
Research Area
- Genetics
- Cell biology
- Molecular biology
Background
- Utilizing low-cost polymers for viral production can enhance accessibility.
- Short hairpin RNAs are critical in gene knockdown strategies.
- Human embryonic stem cells serve as versatile model systems in developmental biology.
Methods Used
- Co-transfection of HEK293T cells to produce lentiviral vectors.
- Use of polyethyleneimine for efficient transfection.
- Ultracentrifugation and filtration techniques for viral particle recovery.
Main Results
- The study reports successful production of lentiviral particles using PEI.
- High transduction efficiency was observed in neural progenitor cells.
- No significant difference in viral titer was noted between PEI and Lipofectamine 3000.
Conclusions
- The findings demonstrate the potential of PEI as a cost-effective reagent for lentiviral vector production.
- This approach is relevant for gene therapy and regenerative medicine research.
Frequently Asked Questions
What is polyethyleneimine (PEI)?
PEI is a cationic polymer used to facilitate the transfection of plasmid DNA into cells.
Why use lentiviral particles?
Lentiviral particles are effective for stable gene expression in dividing and non-dividing cells.
What cells were used in this study?
H9 human embryonic stem cells and H9-derived neural progenitor cells were utilized.
How does this method improve transfection efficiency?
Using PEI enhances the uptake of DNA into cells, leading to more successful transductions.
What advantages does PEI offer compared to traditional methods?
PEI is low-cost and readily available, which makes it an attractive option for large-scale applications.
What are the implications of this research?
The study supports advancements in gene therapy techniques and enhances the potential for future applications in regenerative medicine.
What were the findings regarding cell viability?
Lentiviral transfected cells showed over 80% viability compared to non-transduced control cells.
Executive Industry Relevance
Lentiviral-mediated shRNA delivery using low-cost PEI enables efficient gene knockdown in hESCs and NPCs, supporting early-stage target validation and mechanistic studies. This approach offers scalable, reproducible genetic manipulation for disease modeling and pathway interrogation in preclinical research. The protocol's cost-effectiveness and high transduction efficiency facilitate broader adoption across discovery and translational pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables robust gene silencing to interrogate therapeutic hypotheses in human stem cell-derived systems.
- Supports functional target validation by quantifying gene knockdown effects in relevant cell types.
- Facilitates mechanistic de-risking through controlled manipulation of gene expression.
- Provides a platform for rapid portfolio triage based on genetic dependency data.
Screening & Assay Development
- Generates validated cell models for downstream phenotypic or molecular screening workflows.
- Delivers reproducible and quantitative gene knockdown, supporting assay standardization.
- Enables scalable production of genetically modified cells for high-throughput applications.
- Supports reliable evaluation of compound effects in genetically defined backgrounds.
Translational & Preclinical Research
- Aligns with disease-relevant systems by enabling manipulation in hESC-derived NPCs.
- Maintains pluripotency and differentiation potential, supporting translational continuity.
- Facilitates risk-adjusted advancement decisions by providing predictive genetic models.
- Enables biomarker discovery through targeted gene modulation in preclinical models.
Pipeline & Workflow Integration
This protocol integrates from early discovery through preclinical validation, enabling hypothesis testing, target de-risking, and assay development in human stem cell systems.
- Discovery Biology: Supports null hypothesis testing and pathway clarification via targeted gene knockdown.
- Screening: Provides reproducible, quantitative outputs for assay readiness and compound screening.
- Analytics: Enables measurement of gene expression changes and viability for comparative analysis.
- Translational Research: Maintains disease relevance by preserving differentiation capacity post-transduction.
- Enterprise Reuse: Offers a standardized, scalable workflow for genetic manipulation across multiple projects.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Delivers cost-effective, scalable, and reproducible gene delivery for diverse R&D needs.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enabling robust genetic models.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of discovery programs.
Implementation Considerations
- Requires expertise in lentiviral vector production and stem cell culture.
- Needs access to ultracentrifugation and biosafety infrastructure for viral handling.
- Demands cross-team standardization for reproducible gene delivery and selection.
- Adaptable to various hESC and NPC lines with protocol optimization.
- Dependent on validated shRNA constructs and appropriate controls for interpretation.
Biopharma FAQs
Why is null hypothesis testing critical for shRNA-mediated gene knockdown?
Null hypothesis testing ensures that observed phenotypic changes in hESCs or NPCs are specifically due to targeted gene silencing, supporting rigorous target validation and reducing off-target risk in early discovery.
How does independent variable isolation in lentiviral transduction support discovery pipelines?
Isolating the effect of shRNA delivery allows teams to attribute downstream cellular changes directly to gene knockdown, enabling clear mechanistic insights and informed progression decisions in the pipeline.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative readouts such as gene expression reduction and cell viability provide objective metrics for comparing experimental conditions, supporting reproducibility and robust assay development.
Why are replication requirements important for cross-functional collaboration in shRNA studies?
Replication ensures that gene knockdown effects are consistent across experiments and teams, facilitating data sharing, validation, and integration into broader R&D workflows.
What statistical analysis capabilities are required before implementing shRNA delivery in hESCs?
Teams must apply statistical methods to assess gene knockdown efficiency, viability, and phenotypic outcomes, ensuring that results meet thresholds for significance and inform go/no-go decisions.
Chapters in this video
0:04
Introduction
0:28
Transfection of HEK293T Cells Using Either Polymer Polyethylenimine (PEI) or Lipofectamine 3000 Reagent
2:48
Lentiviral Vectors (LVS) Collection and Ultracentrifugation
5:07
Results: Lentiviral Mediated Delivery of shRNAs in hESCs and NPCs Using Cationic Polymer PEI
6:19
Conclusion
